Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced a new publication for PTI-125, a clinical-stage drug candidate with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE